MCID: PTH002
MIFTS: 49

Pathological Gambling

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

MalaCards integrated aliases for Pathological Gambling:

Name: Pathological Gambling 12 15 17 32
Compulsive Gambling 12 42
Gambling, Pathological 71
Gambling 43

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD9CM 34 312.31
MeSH 43 D005715
NCIt 49 C94335
SNOMED-CT 67 18085000
ICD10 32 F63.0
UMLS 71 C0030662

Summaries for Pathological Gambling

MedlinePlus : 42 Many people enjoy gambling, whether it's betting on a horse or playing poker on the Internet. Most people who gamble don't have a problem, but some lose control of their gambling. Signs of problem gambling include Always thinking about gambling Lying about gambling Spending work or family time gambling Feeling bad after you gamble, but not quitting Gambling with money you need for other things If you have concerns about your gambling, ask for help. Your health care provider can work with you to find the treatment that's best for you. NIH: National Institutes of Health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to depression and sexual disorder. An important gene associated with Pathological Gambling is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Neuroscience. The drugs Methylphenidate and Pramipexole have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 depression 30.7 SLC6A4 MAOA HTR2A
2 sexual disorder 30.3 SLC6A4 HTR2A DRD2
3 stuttering 30.3 SLC6A3 DRD2 DBH
4 traumatic brain injury 30.2 DRD2 COMT
5 neurotic disorder 30.2 SLC6A4 MAOA HTR2A
6 somatization disorder 30.1 SLC6A4 HTR2A
7 intermittent explosive disorder 30.0 SLC6A4 MAOA HTR2A
8 opioid addiction 30.0 DRD2 COMT
9 drug dependence 29.9 SLC6A4 SLC6A3 DRD3 DRD2 DRD1 ANKK1
10 sleep disorder 29.8 SLC6A4 SLC6A3 HTR2A DRD2
11 hyperprolactinemia 29.8 HTR2A DRD4 DRD2 DBH
12 body dysmorphic disorder 29.8 SLC6A4 RTN4 MAOA HTR2A
13 fibromyalgia 29.8 SLC6A4 HTR2A DRD2 COMT
14 cyclothymic disorder 29.7 RTN4 HTR2A DRD4 DRD2
15 dysthymic disorder 29.6 WASF1 SLC6A4 MAOA HTR2A
16 schizoid personality disorder 29.6 WASF1 DRD2
17 movement disease 29.5 SLC6A3 MAOB DRD5 DRD4 DRD3 DRD2
18 anorexia nervosa 29.5 SLC6A4 MAOA HTR2A DRD4 COMT
19 pyromania 29.5 RTN4 MAOA DRD2 DNER
20 alexithymia 29.4 SLC6A4 LOC110806262 DRD2 COMT ANKK1
21 dementia 29.3 SLC6A3 MAOB MAOA HTR2A DRD2 COMT
22 dependent personality disorder 29.3 WASF1 RTN4 DRD4
23 avoidant personality disorder 29.2 WASF1 TPH1 SLC6A4 SLC6A3 MAOA DRD4
24 obsessive-compulsive personality disorder 29.2 WASF1 SLC6A4 HTR2A DRD3
25 schizoaffective disorder 29.2 SLC6A4 HTR2A DRD4 DRD3 DRD2 COMT
26 delusional disorder 29.2 SLC6A3 HTR2A DRD5 DRD4 DRD3 DRD2
27 cocaine abuse 29.2 SLC6A4 SLC6A3 MAOB DRD3 DRD2 DRD1
28 irritable bowel syndrome 29.2 TPH1 SLC6A4 HTR2A COMT
29 bulimia nervosa 29.1 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
30 borderline personality disorder 29.1 TPH1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
31 eating disorder 29.1 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 COMT
32 kleptomania 29.0 SLC6A4 RTN4 MAOA DRD2 DNER ANKK1
33 post-traumatic stress disorder 29.0 SLC6A4 MAOB MAOA HTR2A DRD2 DBH
34 generalized anxiety disorder 29.0 TPH1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
35 bipolar i disorder 29.0 SLC6A4 HTR2A DRD4 DRD3 DRD2 DRD1
36 endogenous depression 28.9 TPH1 SLC6A4 MAOA HTR2A COMT
37 cannabis abuse 28.9 WASF1 DRD4 DRD2 COMT
38 cocaine dependence 28.8 SLC6A4 SLC6A3 MAOB HTR2A DRD3 DRD2
39 separation anxiety disorder 28.8 WASF1 SLC6A4 SLC6A3 RTN4 DRD4
40 anxiety 28.7 TPH1 SLC6A4 SLC6A3 MAOB MAOA HTR2A
41 body mass index quantitative trait locus 11 28.7 SLC6A3 MAOB MAOA HTR2A DRD4 DRD2
42 restless legs syndrome 28.6 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
43 mood disorder 28.6 TPH1 SLC6A4 SLC6A3 MAOB MAOA HTR2A
44 obsessive-compulsive disorder 28.5 TPH1 SLC6A4 SLC6A3 MAOB MAOA HTR2A
45 phobia, specific 28.5 WASF1 SLC6A4 RTN4 MAOA COMT
46 opiate dependence 28.4 TPH1 SLC6A4 SLC6A3 LOC110806262 DRD4 DRD3
47 personality disorder 28.4 TPH1 SLC6A4 SLC6A3 MAOB MAOA HTR2A
48 conduct disorder 28.3 TPH1 SLC6A4 SLC6A3 MAOA DRD5 DRD4
49 agoraphobia 28.3 WASF1 SLC6A4 MAOA LOC110806262 HTR2A COMT
50 social phobia 28.2 WASF1 SLC6A4 MAOA LOC110806262 DRD2 COMT

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

GenomeRNAi Phenotypes related to Pathological Gambling according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 ANKK1 COMT DNAJB6 DRD1 DRD2 DRD3

MGI Mouse Phenotypes related to Pathological Gambling:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 COMT DBH DNER DRD1 DRD2 DRD3
2 cardiovascular system MP:0005385 9.85 COMT DBH DRD1 DRD2 DRD3 DRD5
3 muscle MP:0005369 9.5 DRD1 DRD2 HTR2A SLC6A3 SLC6A4 TPH1
4 nervous system MP:0003631 9.47 COMT DBH DNER DRD1 DRD2 DRD3

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
2
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
3
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Autonomic Agents Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Dopamine Uptake Inhibitors Phase 4
14 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
15 Sympathomimetics Phase 4
16 Protective Agents Phase 4
17
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
18
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
21
Ethanol Approved Phase 3 64-17-5 702
22 Excitatory Amino Acid Antagonists Phase 2, Phase 3
23 Excitatory Amino Acids Phase 2, Phase 3
24 Anesthetics, Dissociative Phase 2, Phase 3
25 Anesthetics, General Phase 2, Phase 3
26 Anesthetics, Intravenous Phase 2, Phase 3
27 Antiemetics Phase 3
28 Gastrointestinal Agents Phase 3
29 Dopamine Agents Phase 3
30 Central Nervous System Depressants Phase 3
31 Antipsychotic Agents Phase 3
32 Tranquilizing Agents Phase 3
33 Dopamine Antagonists Phase 3
34 Psychotropic Drugs Phase 3
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
38
Coal tar Approved Phase 2 8007-45-2
39
Memantine Approved, Investigational Phase 2 19982-08-2 4054
40
Haloperidol Approved Phase 2 52-86-8 3559
41
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
42
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
43
Fluphenazine Approved Phase 2 69-23-8 3372
44
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
45
Milk thistle Approved, Experimental, Investigational Phase 2 65666-07-1
46
Naloxone Approved, Vet_approved Phase 2 465-65-6 5284596
47
Pimavanserin Approved, Investigational Phase 2 706779-91-1 16058810
48
Sertraline Approved Phase 2 79617-96-2 68617
49
Rimonabant Approved, Investigational Phase 2 168273-06-1, 158681-13-1 104850
50
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
4 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
6 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles. Completed NCT01733199 Phase 4
7 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
8 Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
9 Neurocognitive and Metabolic Effects of Mild Hypothyroidism Completed NCT00565864 Phase 4 L-thyroxine (L-T4)
10 An Open Prospective Trial of IV Ketamine in Suicidal Adolescents Unknown status NCT02048423 Phase 2, Phase 3 Ketamine
11 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
12 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
13 Minimal and Brief Treatments for Pathological Gamblers: Developing Effective Treatment Systems Completed NCT00203645 Phase 3
14 Naltrexone Treatment in Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
15 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
16 The Efficacy of Functional Magnetic Resonance Imaging (fMRI) Guided Low Frequency Repetitive Magnetic Transcranial Stimulation (rTMS) Therapy on Symptoms of Generalized Anxiety Disorder (GAD) Completed NCT00662584 Phase 3
17 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
18 Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects Recruiting NCT03227562 Phase 3 RisperiDONE 0.5 MG
19 EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents Active, not recruiting NCT02016378 Phase 3
20 Topiramate in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study Terminated NCT00245583 Phase 3 Topiramate;Placebo
21 RTC of Web Versus In-Person SUD and Comorbidity Treatment Unknown status NCT01529047 Phase 2
22 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
23 Evaluating the Benefits of the Community Reinforcement and Family Training(CRAFT) Approach to Concerned Significant Others(CSO) of Individuals Engaged in Problem Gambling (IPGs) Unknown status NCT01340274 Phase 2
24 A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling Completed NCT00585169 Phase 2 Memantine Hydrochloride
25 Ecopipam Treatment of Pathological Gambling Completed NCT01215357 Phase 2 Ecopipam
26 Tolcapone Treatment of Pathological Gambling: An Open-Label Study Completed NCT00927563 Phase 2 Tolcapone
27 Indicated Prevention With At-Risk Gamblers Completed NCT00078273 Phase 2
28 Double-blind Placebo Controlled Topiramate Trial for Pathological Gamblers Completed NCT01843699 Phase 2 Topiramate flexible dosage;Placebo matching tablets
29 Cognitive Behavioral Therapy for Pathological Gambling Completed NCT00337753 Phase 2
30 Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls Completed NCT02203786 Phase 2 Haloperidol;Fluphenazine;Dexedrine;Placebo
31 Double Blind Controlled Trial of Topiramate for Compulsive Buying Completed NCT02138058 Phase 2 Topiramate
32 Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling Completed NCT01057862 Phase 2 Naltrexone
33 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Completed NCT00967005 Phase 2 N Acetyl Cysteine
34 Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray Completed NCT03223896 Phase 2 Naloxone hydrochloride 20mg/ml
35 Use of Massage Therapy to Reduce Anxiety and Improve Sleep in Patients Participating in an Inpatient Withdrawal Management (Detox) Program: A Randomized Controlled Pilot Study Completed NCT00992979 Phase 2
36 Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study Recruiting NCT02337634 Phase 2 Placebo;Milk Thistle
37 Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder Enrolling by invitation NCT03430180 Phase 2 Naloxone hydrochloride;Placebo
38 Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease Not yet recruiting NCT03947216 Phase 2 Active drug: pimavanserin 17mg (2 strength tablets);Placebo: 2 tablets containing same excipients except active compound
39 Biological Signature and Safety of an Immunomodulatory Probiotic Intervention for Veterans With PTSD Not yet recruiting NCT04150380 Phase 2
40 A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence Terminated NCT00249431 Phase 2 Sertraline
41 Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers Terminated NCT01764685 Phase 2 Topiramate;Placebo
42 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
43 Clinical Assessment of Topiramate on Gambling-Related Behaviours in Problem Gamblers: Effects of Gender and Negative Emotionality Withdrawn NCT00370188 Phase 2 Topiramate
44 Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Unknown status NCT01154712 Phase 1
45 Enhanced Cognitive Behavior Therapy for the Treatment of Pathological Gambling Completed NCT00118391 Phase 1
46 Cognitive Behavioral Treatment for Pathological Gambling Completed NCT00158314 Phase 1
47 Cognitive-Motivational Behavior Therapy for Gamblers Completed NCT00069420 Phase 1
48 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Completed NCT00273702 Phase 1 N-Acetyl Cysteine
49 Acute Effects of Smoked Marijuana on Decision Making, as Assessed by a Modified Gambling Task, in Experienced Marijuana Users Completed NCT00373399 Phase 1 Inactive Marijuana (0% THC);Low THC marijuana (1.8 %THC);High THC marijuana (3.9% THC)
50 Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) Completed NCT01437293 Phase 1 L-dopa / carbidopa / entacapone (LCE)

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

40
Brain, Cortex, Testes, Prefrontal Cortex, Subthalamic Nucleus, Eye, Liver

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 1882)
# Title Authors PMID Year
1
Cognitive Distortions of Patients in the Gambling Addicts' Club - Differences with Regard to Age and Length of Treatment. 42 61
31596824 2019
2
Gambling harm: a global problem requiring global solutions. 42
31443927 2019
3
Public health effects of gambling - debate on a conceptual model. 42
31399026 2019
4
Basolateral amygdala - nucleus accumbens circuitry regulates optimal cue-guided risk/reward decision making. 61
31811876 2020
5
What's in a Name? Evaluating the Public Stigma of Gambling Disorder. 61
31848837 2019
6
A systematic review of gambling-related findings from the National Epidemiologic Survey on Alcohol and Related Conditions. 61
31830810 2019
7
[Gambling and Gaming disorders and physical health of players: A critical review of the literature]. 61
31767247 2019
8
The Multidimensional Structure of Problem Gambling: An Evaluation of Four Gambling Categorization Instruments from an International Online Survey of Gamblers. 61
30793249 2019
9
Factors Precipitating Calls to a Help Hotline: A Comparison of Whites, Blacks, and Hispanics. 61
30604034 2019
10
Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study. 61
31688453 2019
11
[Feasibility study of therapeutic exposure in virtual reality for pathological gamblers]. 61
31761313 2019
12
Behavioral Couples Therapy vs. Cognitive Behavioral Therapy for Problem Gambling: a randomized controlled trial. 61
31746075 2019
13
Mobile Phone Addiction Among Children and Adolescents: A Systematic Review. 61
31800517 2019
14
The Risk of Gambling Problems in the General Population: A Reconsideration. 61
31628592 2019
15
Adult ADHD Is Associated With Gambling Severity and Psychiatric Comorbidity Among Treatment-Seeking Problem Gamblers. 61
28162086 2019
16
An Exploratory Study of Relationships Among Five-Factor Personality Measures and Forms of Gambling in Adults With and Without Probable Pathological Gambling. 61
30382456 2019
17
Religiosity and Chance Beliefs in Persons with DSM-IV Pathological Gambling Enrolled in a Longitudinal Follow-Up Study. 61
31115747 2019
18
[Gambling disorder and imputability: from the nosographic revision to an expanded forensic assessment]. 61
31657803 2019
19
Striatal presynaptic dopaminergic dysfunction in gambling disorder: A 123 I-FP-CIT SPECT study. 61
30226290 2019
20
Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decision-making. 61
29888425 2019
21
Expectation of reward differentially modulates executive inhibition. 61
31443739 2019
22
Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. 61
31423741 2019
23
Overlapping dimensional phenotypes of impulsivity and compulsivity explain co-occurrence of addictive and related behaviors. 61
30458896 2019
24
Effects of nicotine exposure and anxiety on motivation for reward and gambling-like cues under reward uncertainty. 61
30869950 2019
25
Gender Differences in Gambling Exposure and At-risk Gambling Behavior. 61
31471835 2019
26
Addiction beyond pharmacological effects: The role of environment complexity and bounded rationality. 61
31125913 2019
27
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. 61
30848825 2019
28
Prevalence of Gambling Disorder Among Prisoners: A Systematic Review. 61
31315486 2019
29
Let's Call it Quits: Break-Even Effects in the Decision to Stop Taking Risks. 61
30650213 2019
30
Pathological Gambling in a Patient on a Dopamine Agonist. 61
31167528 2019
31
Compulsive sexual behavior disorder in obsessive-compulsive disorder: Prevalence and associated comorbidity. 61
31079471 2019
32
Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. 61
31136681 2019
33
Creativity related to dopaminergic treatment: A multicenter study. 61
30824283 2019
34
Cannabis use, problem-gambling severity, and psychiatric disorders: Data from the national epidemiological survey on alcohol and related conditions. 61
31246071 2019
35
Connecting with a Slot Machine: Social Exclusion and Anthropomorphization Increase Gambling. 61
29959690 2019
36
Youth Gambling in Hong Kong: Prevalence, Psychosocial Correlates, and Prevention. 61
31122548 2019
37
A Systematic Review of Land-Based Self-Exclusion Programs: Demographics, Gambling Behavior, Gambling Problems, Mental Symptoms, and Mental Health. 61
29721719 2019
38
A case of pathological gambling. 61
31142915 2019
39
Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. 61
31082834 2019
40
The relationship between memory associations, gambling involvement, and problem gambling. 61
30579883 2019
41
Locating gambling problems across a continuum of severity: Rasch analysis of the Quinte Longitudinal Study (QLS). 61
30579115 2019
42
Clinical Improvements in Comorbid Gambling/Cocaine Use Disorder (GD/CUD) Patients Undergoing Repetitive Transcranial Magnetic Stimulation (rTMS). 61
31151221 2019
43
Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. 61
30935674 2019
44
Deficits in emotion regulation strategies among problematic and pathological gamblers in a sample of vocational school students. 61
30663330 2019
45
Effects of Gambling Diagnostic Criteria Changes from DSM-IV to DSM-5 on Mental Disorder Comorbidity Across Younger, Middle-Aged, and Older Adults in a Nationally Representative Sample. 61
30167940 2019
46
Addictive Video Game Use: An Emerging Pediatric Problem? 61
30946788 2019
47
Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. 61
30753324 2019
48
Cognitive bias modification in problem and pathological gambling using a web-based approach-avoidance task: A pilot trial. 61
30583260 2019
49
Nancy M. Petry (1968-2018). 61
30762395 2019
50
Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. 61
30671764 2019

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 DRD5 DRD4 DRD3 DRD2 DRD1
2 12.47 TPH1 RTN4 DBH COMT
3 12.3 DRD5 DRD4 DRD3 DRD2 DRD1
4
Show member pathways
12.28 SLC6A3 MAOB MAOA DRD5 DRD4 DRD3
6
Show member pathways
12.09 DRD5 DRD4 DRD2 DRD1
7 12.07 TPH1 SLC6A4 MAOA HTR2A
8
Show member pathways
11.95 SLC6A3 MAOB MAOA DRD2 DRD1
9 11.92 TPH1 SLC6A4 MAOB MAOA HTR2A
10
Show member pathways
11.81 DRD4 DRD3 DRD2
11 11.8 HTR2A DRD4 DRD3
12
Show member pathways
11.74 TPH1 MAOB MAOA
13 11.73 TPH1 MAOA DBH
14
Show member pathways
11.72 MAOB MAOA DBH COMT
15 11.71 HTR2A DRD2 DRD1
16
Show member pathways
11.69 TPH1 MAOB MAOA
17
Show member pathways
11.67 HTR2A DRD5 DRD4 DRD3 DRD2 DRD1
18
Show member pathways
11.43 SLC6A4 SLC6A3 MAOA DBH
19 11.15 TPH1 SLC6A4 MAOA HTR2A
20
Show member pathways
11.08 SLC6A4 SLC6A3 MAOA COMT
21 10.97 DRD5 DRD3 DRD2 DRD1
22 10.93 DRD2 ANKK1
23
Show member pathways
10.9 TPH1 MAOA DBH COMT
24
Show member pathways
10.88 MAOB MAOA COMT
25 10.83 MAOB MAOA COMT
26
Show member pathways
10.73 MAOB MAOA
27
Show member pathways
10.73 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.39 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
2 integral component of membrane GO:0016021 10.21 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
3 cell GO:0005623 10.02 RTN4 HTR2A DRD5 DRD4 DRD3 DRD2
4 integral component of plasma membrane GO:0005887 10.01 SLC6A4 SLC6A3 HTR2A DRD5 DRD4 DRD3
5 glutamatergic synapse GO:0098978 9.83 HTR2A DRD4 DRD3 DRD2 DRD1
6 dendrite GO:0030425 9.73 HTR2A DRD4 DRD2 DRD1 DNER COMT
7 GABA-ergic synapse GO:0098982 9.67 DRD3 DRD2 DRD1
8 ciliary membrane GO:0060170 9.63 DRD5 DRD2 DRD1
9 non-motile cilium GO:0097730 9.5 DRD5 DRD2 DRD1
10 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR2A DRD2 DRD1
11 dopaminergic synapse GO:0098691 9.33 SLC6A3 DRD3 DRD2
12 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 SLC6A3 HTR2A DRD2 DRD1

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.02 HTR2A DRD5 DRD4 DBH
2 response to drug GO:0042493 9.97 SLC6A4 SLC6A3 MAOB HTR2A DRD3 DRD2
3 response to ethanol GO:0045471 9.96 SLC6A3 MAOB DRD3 DRD2
4 cellular calcium ion homeostasis GO:0006874 9.95 HTR2A DRD5 DRD4 DRD3
5 response to toxic substance GO:0009636 9.94 SLC6A4 MAOB DRD3 DRD2
6 locomotory behavior GO:0007626 9.93 SLC6A3 DRD3 DRD2 DRD1 DBH
7 memory GO:0007613 9.92 SLC6A4 HTR2A DRD1 DBH
8 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.91 DRD5 DRD3 DRD2 DRD1
9 learning GO:0007612 9.88 DRD3 DRD1 COMT
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 HTR2A DRD4 DRD1
11 synapse assembly GO:0007416 9.88 DRD2 DRD1 DNER
12 regulation of synaptic vesicle exocytosis GO:2000300 9.87 HTR2A DRD2 DRD1
13 visual learning GO:0008542 9.87 DRD3 DRD2 DRD1 DBH
14 social behavior GO:0035176 9.86 SLC6A4 DRD4 DRD3
15 associative learning GO:0008306 9.86 DRD5 DRD2 DRD1 DBH
16 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.85 DRD3 DRD2 DRD1
17 regulation of dopamine secretion GO:0014059 9.84 HTR2A DRD3 DRD2
18 negative regulation of blood pressure GO:0045776 9.83 DRD5 DRD3 DRD2
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.83 DRD5 DRD3 DRD2 DRD1
20 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
21 negative regulation of protein secretion GO:0050709 9.81 DRD4 DRD3 DRD2
22 temperature homeostasis GO:0001659 9.8 HTR2A DRD2 DRD1
23 dopamine receptor signaling pathway GO:0007212 9.8 DRD4 DRD3 DRD2 DRD1
24 response to cocaine GO:0042220 9.8 SLC6A3 DRD5 DRD3 DRD2 DRD1
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
26 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.79 HTR2A DRD3 DRD2
27 prepulse inhibition GO:0060134 9.78 SLC6A3 DRD3 DRD2 DRD1
28 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.77 DRD5 DRD3 DRD1
29 neurotransmitter catabolic process GO:0042135 9.77 MAOB MAOA COMT
30 regulation of dopamine metabolic process GO:0042053 9.76 SLC6A3 DRD4 DRD1
31 behavioral response to ethanol GO:0048149 9.76 DRD4 DRD3 DRD2 DBH
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.75 DRD4 DRD3 DRD2
33 response to pain GO:0048265 9.74 DBH COMT
34 positive regulation of kinase activity GO:0033674 9.74 HTR2A DRD4
35 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
36 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
37 transmission of nerve impulse GO:0019226 9.74 DRD5 DRD1
38 long-term synaptic depression GO:0060292 9.73 DRD5 DRD1
39 neurotransmitter biosynthetic process GO:0042136 9.73 SLC6A4 SLC6A3
40 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
41 grooming behavior GO:0007625 9.73 DRD2 DRD1
42 G protein-coupled receptor internalization GO:0002031 9.73 DRD3 DRD2
43 striatum development GO:0021756 9.73 DRD2 DRD1
44 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD5 DRD3 DRD2 DRD1
45 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.72 DRD4 DRD3
46 maternal behavior GO:0042711 9.72 DRD1 DBH
47 regulation of potassium ion transport GO:0043266 9.72 DRD3 DRD2
48 peristalsis GO:0030432 9.72 DRD2 DRD1
49 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.72 DRD3 DRD2 DRD1
50 behavioral response to cocaine GO:0048148 9.72 HTR2A DRD4 DRD3 DRD2 DRD1

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.93 HTR2A DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.65 SLC6A3 HTR2A DRD4 DRD3 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD4 DRD3 DRD2
4 neurotransmitter:sodium symporter activity GO:0005328 9.49 SLC6A4 SLC6A3
5 serotonin binding GO:0051378 9.48 SLC6A4 HTR2A
6 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
7 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A4 SLC6A3
8 primary amine oxidase activity GO:0008131 9.4 MAOB MAOA
9 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
10 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
11 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....